Cited by 1,993Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Open access

Ding, Li, Ley, Timothy J., Larson, David E., Miller, Christopher A., Koboldt, Daniel C., Welch, John S., Ritchey, Julie K., Young, Margaret A., Lamprecht, Tamara, McLellan, Michael D., McMichael, Joshua F., Wallis, John W., Lu, Charles, Shen, Dong, Harris, Christopher C., Dooling, David J., Fulton, Robert S., Fulton, Lucinda L., Chen, Ken, Schmidt, Heather, Kalicki-Veizer, Joelle, Magrini, Vincent J., Cook, Lisa, McGrath, Sean D., Vickery, Tammi L., Wendl, Michael C., Heath, Sharon, Watson, Mark A., Link, Daniel C., Tomasson, Michael H., Shannon, William D., Payton, Jacqueline E., Kulkarni, Shashikant, Westervelt, Peter, Walter, Matthew J., Graubert, Timothy A., Mardis, Elaine R., Wilson, Richard K., DiPersio, John F.·2012·Nature

DOI 10.1038/nature10738PMC PMC3267864

Open this paper in CoChat — free account Open PDF

Abstract

The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature10738

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citation
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citation
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citation
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489

Show all 30 references

Sorted by citations

Items 401–500 of 999

Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia
Wakita, S., Yamaguchi, H., Omori, I., Terada, K., Ueda, T., Manabe, E., Kurosawa, S., Iida, S., Ibaraki, T., Sato, Y., et al. (2012) · Leukemia · doi:10.1038/leu.2012.317 · Cited by 90
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
Sun, Q.-Y., Ding, L.-W., Tan, K. T., Chien, W., Mayakonda, A., Lin, D.-C., Loh, X.-Y., Xiao, J.-F., Meggendorfer, M., Alpermann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2016.160 · Cited by 87
Intratumor heterogeneity: Nature and biological significance
Gerashchenko, T. S., Denisov, E. V., Литвяков, Н. В., Zavyalova, M. V., Vtorushin, S. V., Tsyganov, M. M., Михайлович, П. В., & Чердынцева, Н. В. (2013) · Biochemistry (Moscow) · doi:10.1134/s0006297913110011 · Cited by 86
Clonal Architectures and Driver Mutations in Metastatic Melanomas
Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 85
Single cell analysis of clonal architecture in acute myeloid leukaemia
Potter, N. E., Miraki‐Moud, F., Ermini, L., Titley, I., Vijayaraghavan, G., Papaemmanuil, E., Campbell, P. J., Gribben, J. G., Taussig, D. C., & Greaves, M. F. (2018) · Leukemia · doi:10.1038/s41375-018-0319-2 · Cited by 92
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Goldman, S. L., Hassan, C., Khunte, M., Soldatenko, A., Jong, Y., Afshinnekoo, E., & Mason, C. E. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00133 · Cited by 90
Microfluidics as an Enabling Technology for Personalized Cancer Therapy
Mathur, L., Ballinger, M., Utharala, R., & Merten, C. A. (2019) · Small · doi:10.1002/smll.201904321 · Cited by 83
The serum tryptase test: an emerging robust biomarker in clinical hematology
Valent, P., Sperr, W. R., Sotlar, K., Reiter, A., Akin, C., Gotlib, J., Horny, H.-P., & Arock, M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.955008 · Cited by 83
Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia
Gamis, A. S., Alonzo, T. A., Perentesis, J. P., & Meshinchi, S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24432 · Cited by 83
Biallelic DICER1 Mutations in Sporadic Pleuropulmonary Blastoma
Seki, M., Yoshida, K., Shiraishi, Y., Shimamura, T., Sato, Y., Nishimura, R., Okuno, Y., Chiba, K., Tanaka, H., Kato, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2470 · Cited by 82
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
Minagawa, K., Jamil, M. O., Al‐Obaidi, M., Pereboeva, L., Salzman, D. E., Erba, H. P., Lamb, L. S., Bhatia, R., Mineishi, S., & Stasi, A. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166891 · Cited by 83
Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies
Balça-Silva, J., Matias, D., do Carmo, A., Sarmento‐Ribeiro, A. B., Lopes, M. C., & Moura‐Neto, V. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.007 · Cited by 82
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation
Kunz, J. B., Rausch, T., Bandapalli, O. R., Eilers, J., Richter‐Pechańska, P., Schuessele, S., Assenov, Y., Stütz, A. M., Kirschner‐Schwabe, R., Hof, J., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.129692 · Cited by 82
Genome evolution in ductal carcinoma in situ: invasion of the clones
Casasent, T. D., Edgerton, M. E., & Navin, N. E. (2016) · The Journal of Pathology · doi:10.1002/path.4840 · Cited by 84
Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer
Kansara, S., Pandey, V., Lobie, P. E., Sethi, G., Garg, M., & Pandey, A. K. (2020) · Cells · doi:10.3390/cells9061511 · Cited by 85
DDX41 is required for cGAS-STING activation against DNA virus infection
Singh, R. S., Vidhyasagar, V., Yang, S., Arna, A. B., Yadav, M., Aggarwal, A., Aguilera, A. N., Shinriki, S., Bhanumathy, K. K., Pandey, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110856 · Cited by 85
Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor
Kuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 80
Using single‐cell multiple omics approaches to resolve tumor heterogeneity
Ortega, M. A., Poirion, O., Zhu, X., Huang, S., Wolfgruber, T. K., Sebra, R., & Garmire, L. X. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0177-y · Cited by 81
Targeting cancer stem cells in squamous cell carcinoma
Chen, D., & Wang, C. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz016 · Cited by 83
Pharmacogenomic biomarkers for personalized cancer treatment
Rodríguez‐Antona, C., & Tarón, M. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12321 · Cited by 82
Recent Progress on Circular RNA Research in Acute Myeloid Leukemia
Jamal, M., Song, T., Chen, B., Faisal, M., Hong, Z., Xie, T., Wu, Y., Pan, S., Yin, Q., Shao, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01108 · Cited by 80
Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
Hollebecque, A., Malka, D., Ferté, C., Ducreux, M. P., & Boige, V. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.005 · Cited by 79
Anti-Neuroinflammatory Effects of the Calcium Channel Blocker Nicardipine on Microglial Cells: Implications for Neuroprotection
Huang, B., Chang, P.-C., Yeh, W., Lee, C., Tsai, C., Lin, C., Lin, H., Liu, Y.-S., Wu, C. Y.-J., Ko, P.-Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091167 · Cited by 80
A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data
Li, B., & Li, J. Z. (2014) · Genome biology · doi:10.1186/s13059-014-0473-4 · Cited by 76
SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment
Mian, S. A., Rouault‐Pierre, K., Smith, A., Seidl, T., Pizzitola, I., Kizilors, A., Kulasekararaj, A. G., Bonnet, D. A., & Mufti, G. J. (2015) · Nature Communications · doi:10.1038/ncomms10004 · Cited by 87
Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
Masouridi‐Levrat, S., Simonetta, F., & Chalandon, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00362 · Cited by 79
Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target
Tomecki, R., Drążkowska, K., Kuciński, I., Stoduś, K., Szczęsny, R. J., Gruchota, J., Owczarek, E. P., Kalisiak, K., & Dziembowski, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt930 · Cited by 79
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Quek, L. S., Ferguson, P., Metzner, M., Ahmed, I., Kennedy, A., Garnett, C., Jeffries, S., Walter, C. U., Piechocki, K., Timbs, A., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000760 · Cited by 81
Potential targeting of FLT3 acute myeloid leukemia
Ambinder, A. J., & Levis, M. J. (2020) · Haematologica · doi:10.3324/haematol.2019.240754 · Cited by 80
Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome
Nikolaev, S. I., Santoni, F. A., Vannier, A., Falconnet, E., Giarin, E., Basso, G., Hoischen, A., Veltman, J. A., Groet, J., Nižetić, D., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491936 · Cited by 80
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
Vikova, V., Jourdan, M., Robert, N., Requirand, G., Boireau, S., Bruyer, A., Vincent, L., Cartron, G., Klein, B., Elemento, O., et al. (2019) · Theranostics · doi:10.7150/thno.28374 · Cited by 76
Cohesin Mutations in CancerPreprint
Koninck, M. D., & Losada, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026476 · Cited by 82
How I treat FLT3-mutated AML
Pratz, K. W., & Levis, M. J. (2016) · Blood · doi:10.1182/blood-2016-09-693648 · Cited by 77
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Aitken, M. J. L., Ravandi, F., Patel, K. P., & Short, N. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01148-5 · Cited by 79
HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncologyPreprint
Shrestha, R., Hodzic, E., Sauerwald, T., Dao, P., Wang, K., Yeung, J., Anderson, S. A., Vandin, F., Haffari, G., Collins, C. C., et al. (2017) · Genome Research · doi:10.1101/gr.221218.117 · Cited by 77
Diagnostic Applications of High-Throughput DNA Sequencing
Boyd, S. D. (2012) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164026 · Cited by 78
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
Wilmott, J. S., Tembe, V., Howle, J. R., Sharma, R. N., Thompson, J. F., Rizos, H., Lo, R. S., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0530 · Cited by 76
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B ‐cell acute lymphoblastic leukemia
Jabbour, E. J., Short, N. J., Jorgensen, J. L., Yilmaz, M. E., Ravandi, F., Wang, S. A., Thomas, D. A., Khoury, J. D., Champlin, R. E., Khouri, I. F., et al. (2016) · Cancer · doi:10.1002/cncr.30264 · Cited by 78
Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1
Benedetti, L. G., Cereda, M., Monteverde, L., Desai, N., & Ciccarelli, F. D. (2017) · Oncotarget · doi:10.18632/oncotarget.16838 · Cited by 81
Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment
West, J., Ma, Y., & Newton, P. K. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.07.028 · Cited by 76
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Heider, M., Nickel, K., Högner, M., & Bassermann, F. C. (2021) · Oncology Research and Treatment · doi:10.1159/000520312 · Cited by 85
Clonality and Evolutionary History of Rhabdomyosarcoma
Chen, L., Shern, J. F., Wei, J. S., Yohe, M. E., Song, Y., Hurd, L., Liao, H., Catchpoole, D. R., Skapek, S. X., Barr, F. G., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005075 · Cited by 77
Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia
Bochtler, T., Stölzel, F., Heilig, C. E., Kunz, C., Mohr, B., Jauch, A. S., Janssen, J. W. G., Krämer, M., Benner, A., Bornhäuser, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7921 · Cited by 76
Dynamic evolution of clonal epialleles revealed by methclone
Li, S., Garrett-Bakelman, F. E., Perl, A. E., Luger, S. M., Zhang, C., To, B. L., Lewis, I. D., Brown, A. L., D’Andrea, R. J., Ross, M. E., et al. (2014) · Genome biology · doi:10.1186/preaccept-3452801621370693 · Cited by 71
Translating Genomics for Precision Cancer Medicine
Roychowdhury, S., & Chinnaiyan, A. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025552 · Cited by 75
Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy
Pouchol, C., Clairambault, J., Lorz, A., & Trélat, E. (2017) · Journal de Mathématiques Pures et Appliquées · doi:10.1016/j.matpur.2017.10.007 · Cited by 75
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
Hazar-Rethinam, M. H., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 77
The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
Wang, L., Yang, Q., Peng, S., & Liu, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s212465 · Cited by 83
Adaptive Evolution in Ecological Communities
Turcotte, M. M., Corrin, M. S. C., & Johnson, M. T. J. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001332 · Cited by 75
The three-dimensional cancer genome
Corces, M. R., & Corces, V. G. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.002 · Cited by 77
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Ghiaur, G., & Levis, M. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.005 · Cited by 75
DNA Mutations May Not Be the Cause of Cancer
Adjiri, A. (2017) · Oncology and Therapy · doi:10.1007/s40487-017-0047-1 · Cited by 76
Advances for studying clonal evolution in cancer
Ding, L., Raphael, B. J., Chen, F., & Wendl, M. C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.028 · Cited by 74
Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology
Sasaki, N., & Clevers, H. C. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.09.001 · Cited by 75
Clinical utility of whole-genome sequencing in precision oncology
Rosenquist, R., Cuppen, E. P. J. G., Buettner, R., Caldas, C., Dreau, H. M.-P., Elemento, O., Frederix, G., Grimmond, S. M., Haferlach, T., Jobanputra, V., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.018 · Cited by 73
Application of single-cell genomics in cancer: promise and challenges
Wills, Q. F., & Mead, A. J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv235 · Cited by 77
Breast cancer intratumor genetic heterogeneity: causes and implications
Ng, C. K. Y., Pemberton, H. N., & Reis-Filho, J. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.85 · Cited by 77
A personalized view on cancer immunotherapy
Wayteck, L., Breckpot, K., Demeester, J., Smedt, S. C. D., & Raemdonck, K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.016 · Cited by 82
EphA3 biology and cancer
Janes, P. W., Slape, C. I., Farnsworth, R. H., Atapattu, L., Scott, A. M., & Vail, M. E. (2014) · Growth Factors · doi:10.3109/08977194.2014.982276 · Cited by 75
Classification and risk assessment in AML: integrating cytogenetics and molecular profiling
Moarii, M., & Papaemmanuil, E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.37 · Cited by 76
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma
Johanns, T. M., Miller, C. A., Liu, C. J., Perrin, R. J., Bender, D. E., Kobayashi, D. K., Campian, J. L., Chicoine, M. R., Dacey, R. G., Huang, J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1561106 · Cited by 75
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
Wang, J., Khiabanian, H., Rossi, D., Fabbri, G., Gattei, V., Forconi, F., Laurenti, L., Marasca, R., Poeta, G. D., Foà, R., et al. (2014) · eLife · doi:10.7554/elife.02869 · Cited by 71
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
Nahas, M. R., Stroopinsky, D., Rosenblatt, J. M., Cole, L., Pyzer, A. R., Anastasiadou, E., Сергеева, А., Ephraim, A., Washington, A. J., Orr, S., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15818 · Cited by 74
Clinical Implications of Inflammation in Acute Myeloid Leukemia
Récher, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.623952 · Cited by 80
Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
Bukhari, S. N. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040866 · Cited by 74
Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations
Yang, F., Petsalaki, E., Rolland, T., HILL, D. E., Vidal, M., & Roth, F. P. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004147 · Cited by 71
Aberrant splicing and drug resistance in AML
de Necochea-Campion, R., Shouse, G. P., Zhou, Q., Mirshahidi, S., & Chen, C.-S. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0315-9 · Cited by 66
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion
Gümüşkaya, B., Gürel, B., Fedor, H. L., Tan, H.-L., Weier, C. A., Hicks, J. L., Haffner, M. C., Lotan, T. L., & Marzo, A. M. D. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.8 · Cited by 72
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding
Schoofs, T., Rohde, C., Hebestreit, K., Klein, H., Göllner, S., Schulze, I., Lerdrup, M., Dietrich, N., Singh, S. A., Witten, A., et al. (2012) · Blood · doi:10.1182/blood-2012-08-448860 · Cited by 71
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability
Shlush, L. I., Chapal-Ilani, N., Adar, R., Pery, N., Maruvka, Y. E., Spiro, A., Shouval, R., Rowe, J. M., Tzukerman, M., Bercovich, D., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388629 · Cited by 72
OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues
Wunderlich, M., Brooks, R. A., Panchal, R., Rhyasen, G. W., Danet-Desnoyers, G. A., & Mulloy, J. C. (2014) · Blood · doi:10.1182/blood-2014-02-556340 · Cited by 72
Genomic Landscapes and Clonality of De Novo AML
Miller, C. A., Wilson, R. K., & Ley, T. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1308782 · Cited by 70
The 3' to 5' Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human Disease
Robinson, S., Oliver, A., Chevassut, T., & Newbury, S. (2015) · Biomolecules · doi:10.3390/biom5031515 · Cited by 71
Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer
Hu, W., Fan, C., Jiang, P., Ma, Z., Yan, X., Di, S., Jiang, S., Li, T. X., Cheng, Y., & Yang, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6228 · Cited by 72
DNA methyltransferases in hematological malignancies
Hoang, N.-M., & Rui, L. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.04.006 · Cited by 76
Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing
Xie, T., Cho, Y. B., Wang, K., Huang, D., Hong, H. K., Choi, Y., Ko, Y. H., Nam, D., Jin, J., Yang, H., et al. (2014) · Genomics · doi:10.1016/j.ygeno.2014.07.012 · Cited by 70
Targeting FLT3 to treat leukemia
Koenig, H., & Levis, M. J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.960843 · Cited by 72
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia
Zhou, J. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i4.473 · Cited by 74
Heterogeneity in Melanoma
Shannan, B., Perego, M., Somasundaram, R., & Herlyn, M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_1 · Cited by 70
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
Sveen, A., Løes, I. M., Alagaratnam, S., Nilsen, G., Høland, M., Lingjærde, O. C., Sørbye, H., Berg, K. C. G., Horn, A., Angelsen, J., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006225 · Cited by 69
Genome sequencing and cancer
Mardis, E. R. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.03.005 · Cited by 69
The molecular spectrum and clinical impact of DIS 3 mutations in multiple myeloma
Weißbach, S., Langer, C., Puppe, B., Nedeva, T., Bach, E., Kull, M., Bargou, R. C., Einsele, H., Rosenwald, A., Knop, S. T., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13256 · Cited by 67
Genetic predisposition to leukemia and other hematologic malignancies
Feurstein, S. K., Drazer, M. W., & Godley, L. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.003 · Cited by 66
A survey and evaluation of Web-based tools/databases for variant analysis of TCGA data
Zhang, Z., Li, H., Jiang, S., Li, R., Li, W., Chen, H., & Bo, X. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby023 · Cited by 73
Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding
Belderbos, M. E., Koster, T., Dethmers-Ausema, B., Jacobs, S., Sowdagar, S., Zwart, E., de Bont, E. S., de Haan, G., & Bystrykh, L. V. (2017) · Blood · doi:10.1182/blood-2016-12-758250 · Cited by 68
Pediatric Acute Myeloid Leukemia
Tarlock, K., & Meshinchi, S. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.007 · Cited by 73
Targeting novel signaling pathways for resistant acute myeloid leukemia
Sakamoto, K. M., Grant, S., Saleiro, D., Crispino, J. D., Hijiya, N., Giles, F. J., Platanias, L. C., & Eklund, E. A. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.017 · Cited by 69
SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing
Niknafs, N., Guthrie, V. B., Naiman, D. Q., & Karchin, R. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004416 · Cited by 68
Comparing somatic mutation-callers: beyond Venn diagrams
Kim, S. Y., & Speed, T. P. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-189 · Cited by 66
A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
Kirtonia, A., Pandya, G., Sethi, G., Pandey, A. K., Das, B. C., & Garg, M. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01944-5 · Cited by 68
Ribosome biogenesis and function in development and disease
Ni, C., & Buszczak, M. (2023) · Development · doi:10.1242/dev.201187 · Cited by 67
Quizartinib for the Treatment of FLT3/ITD Acute Myeloid Leukemia
Levis, M. J. (2014) · Future Oncology · doi:10.2217/fon.14.105 · Cited by 67
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG), Gaidzik, V. I., Weber, D., Paschka, P., Kaumanns, A., Krieger, S., Corbacioglu, A., Krönke, J., Kapp‐Schwoerer, S., Kraemer, D. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.200 · Cited by 69
Intra-tumor genetic heterogeneity in rectal cancer
Hardiman, K. M., Ulintz, P., Kuick, R. D., Hovelson, D. H., Gates, C., Bhasi, A., Grant, A. R., Liu, J., Cani, A. K., Greenson, J. K., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.131 · Cited by 66
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias
Wang, K., Sánchez-Martín, M., Wang, X., Knapp, K. M., Koche, R. P., Vu, L., Nahas, M. K., He, J., Hadler, M., Stein, E. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.166 · Cited by 67
Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes
Khan, F. H., Pandian, V., Ramraj, S., Natarajan, M., Aravindan, S., Herman, T. S., & Aravindan, N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1463-y · Cited by 66
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
Thomas, D., Powell, J. A., Vergez, F., Segal, D., Nguyen, N.-Y. N., Baker, A., Teh, T., Barry, E. F., Sarry, J., Lee, E. M., et al. (2013) · Blood · doi:10.1182/blood-2012-08-447441 · Cited by 66
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics
Landau, D. A., & Wu, C. J. (2013) · Genome Medicine · doi:10.1186/gm451 · Cited by 70
Whole‐exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia
Shiba, N., Yoshida, K., Shiraishi, Y., Okuno, Y., Yamato, G., Hara, Y., Nagata, Y., Chiba, K., Tanaka, H., Terui, K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14247 · Cited by 67

Authors: Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Ley, Timothy J.
ORCID: Ding, Li
Ley, Timothy J.
Larson, David E.
Miller, Christopher A.
Koboldt, Daniel C.
Welch, John S.
Ritchey, Julie K.
McLellan, Michael D.
McMichael, Joshua F.
Lu, Charles
Shen, Dong
Fulton, Robert S.
Fulton, Lucinda L.
Chen, Ken
Magrini, Vincent J.
McGrath, Sean D.
Vickery, Tammi L.
Wendl, Michael C.
Heath, Sharon
Watson, Mark A.
Link, Daniel C.
Tomasson, Michael H.
Payton, Jacqueline E.
Kulkarni, Shashikant
Walter, Matthew J.
Graubert, Timothy A.
Mardis, Elaine R.
Wilson, Richard K.
DiPersio, John F.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-01
Volume: 481
Issue: 7382
Pages: 506-510
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10738
PMC: PMC3267864
OpenAlex: W2093144236
Cited by: 1,993
References: 30
Citations by year: 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
FWCI: 149.48
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
Locations: Nature (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Foundation for Barnes-Jewish Hospital (00335-0505-02)
National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
MeSH terms: Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks